Sarepta target upped to $220 from $165 by Morgan Stanley

Maintains  Overweight

https://www.benzinga.com/stock/SRPT/ratings

Ryman Hospital Properties cut to Underweight from Neutral by JPMorgan

Target to $77 from $80

https://www.benzinga.com/stock/RHP/ratings

NextCure started at Buy by B of A

https://www.benzinga.com/stock/NXTC/ratings

Intellia Therapeutics started at Outperform by Baird

Target $23

https://www.benzinga.com/stock/NTLA/ratings

Myriad cut to Market Perform by Cowen

From Outperform

https://www.benzinga.com/stock/MYGN/ratings

Artelo Biosciences started at Buy by Maxim

Target $8

https://www.benzinga.com/stock/ARTL/ratings

Apellis started at Outperform by Oppenheimer

Target $52

https://www.benzinga.com/stock/APLS/ratings